ACADIA Pharmaceuticals Inc. (ACAD) – What Are Researchers Saying About This Stock?

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are currently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $31.34.

A number of research analysts recently issued reports on ACAD shares. Citigroup reiterated a “buy” rating and issued a $33.00 price objective (down from $40.00) on shares of ACADIA Pharmaceuticals in a report on Friday, September 25th. Oppenheimer reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, September 23rd. Deutsche Bank decreased their price target on shares of ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday. Finally, Morgan Stanley dropped their price target on shares of ACADIA Pharmaceuticals from $28.00 to $24.00 and set an “equal weight” rating for the company in a research note on Friday.

Read Our Latest Stock Report on ACAD

ACADIA Pharmaceuticals Trading Up 3.4%

ACAD traded up $0.61 on Friday, reaching $18.75. The stock had a trading volume of 1,784,886 shares, compared to its average volume of 2,701,394. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of 8.89 and a beta of 0.87. ACADIA Pharmaceuticals has a fifty-two week low of $15.85 and a fifty-two week high of $30.96. The firm has a 50-day moving average of $21.79 and a 200-day moving average of $23.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.11. The firm had revenue of $342.30 million for the quarter, compared to analyst estimates of $332.58 million. ACADIA Pharmaceuticals had a return on equity of 8.90% and a net margin of 30.13%. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share. Sell-side analysts anticipate that ACADIA Pharmaceuticals will post 0.76 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Mark Schneyer sold 3,321 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the completion of the sale, the executive vice president directly owned 71,322 shares in the company, valued at $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 26.20% of the stock is owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ACAD. BlackRock Inc. bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth about $569,634,000. First Trust Advisors LP lifted its stake in shares of ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after acquiring an additional 1,073,834 shares during the period. Dimensional Fund Advisors LP boosted its holdings in ACADIA Pharmaceuticals by 8.0% in the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after acquiring an additional 234,186 shares during the last quarter. Palo Alto Investors LP bought a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $72,461,629. Finally, Renaissance Technologies LLC boosted its holdings in ACADIA Pharmaceuticals by 12.5% in the first quarter. Renaissance Technologies LLC now owns 1,724,196 shares of the biopharmaceutical company’s stock valued at $38,381,000 after acquiring an additional 191,600 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

(Get Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

Featured Stories

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.